|
1
|
Lansdorpvogelaar I and Kuipers EJ:
Screening for gastric cancer in Western countries. Gut. 65:543–544.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Apicella M, Corso S and Giordano S:
Targeted therapies for gastric cancer: Failures and hopes from
clinical trials. Oncotarget. 8:57654–57669. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsuji T, Ibaragi S and Hu GF:
Epithelial-mesenchymal transition and cell cooperativity in
metastasis. Cancer Res. 69:7135–7139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roussos ET, Keckesova Z, Haley JD, Epstein
DM, Weinberg RA and Condeelis JS: AACR special conference on
epithelial-mesenchymal transition and cancer progression and
treatment. Cancer Res. 70:7360–7364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marais A, Ji Z, Child ES, Krause E, Mann
DJ and Sharrocks AD: Cell Cycle-dependent regulation of the
forkhead transcription factor FOXK2 by CDK·cyclin complexes. J Biol
Chem. 285:35728–35739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qian Y, Xia S and Feng Z: Sox9 mediated
transcriptional activation of FOXK2 is critical for colorectal
cancer cells proliferation. Biochem Biophys Res Commun. 29:475–481.
2017. View Article : Google Scholar
|
|
8
|
Shi Z, Liu J, Yu X, Huang J, Shen S, Zhang
Y, Han R, Ge N and Yang Y: Loss of FOXF2 expression predicts poor
prognosis in hepatocellular carcinoma patients. Ann Surg Oncol.
23:211–217. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen S, Jiang S, Hu F, Xu Y, Wang T and
Mei Q: Foxk2 inhibits non-small cell lung cancer
epithelial-mesenchymal transition and proliferation through the
repression of different key target genes. Oncol Rep. 37:2335–2347.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shan L, Zhou X, Liu X, Wang Y, Su D, Hou
Y, Yu N, Yang C, Liu B, Gao J, et al: FOXK2 elicits massive
transcription repression and suppresses the hypoxic response and
breast cancer carcinogenesis. Cancer Cell. 30:708–722. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nestal de Moraes G, Khongkow P, Gong C,
Yao S, Gomes AR, Ji Z, Kandola N, Delbue D, Man EP, Khoo US, et al:
Forkhead box K2 modulates epirubicin and paclitaxel sensitivity
through FOXO3a in breast cancer. Oncogenesis. 4:e1672015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen X, Ji Z, Webber A and Sharrocks AD:
Genome-wide binding studies reveal DNA binding specificity
mechanisms and functional interplay amongst Forkhead transcription
factors. Nucleic Acids Res. 44:1566–1578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bowman CJ, Ayer DE and Dynlacht BD: Foxk
proteins repress the initiation of starvation-induced atrophy and
autophagy programs. Nat Cell Biol. 16:1202–1214. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi Z, Qian X, Li L, Zhang J, Zhu S, Zhu
J, Chen L, Zhang K, Han L, Yu S, et al: Nuclear translocation of
β-catenin is essential for glioma cell survival. J Neuroimmune
Pharmacol. 7:892–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi IJ, Lee NR, Kim SG, Lee WS, Park SJ,
Kim JJ, Lee JH, Kwon JW, Park SH, You JH, et al: Short-term
outcomes of endoscopic submucosal dissection in patients with early
gastric cancer: A prospective multicenter cohort study. Gut Liver.
10:739–748. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo JG, Guo CC, He ZQ, Cai XY and Mou YG:
High MMP-26 expression in glioma is correlated with poor clinical
outcome of patients. Oncol Lett. 16:2237–2242. 2018.PubMed/NCBI
|
|
19
|
Aoyama T, Yoshikawa T, Fujikawa H, Hayashi
T, Ogata T, Cho H, Yamada T, Hasegawa S, Tsuchida K, Yukawa N, et
al: Prognostic factors in stage IB gastric cancer. World J
Gastroenterol. 20:6580–6585. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maounis NF, Dráberová E, Trakas N, Chorti
M, Riga D, Tzannis K, Kanakis M, Voralu K, Ellina E, Mahera E, et
al: Expression of γ-tubulin in non-small cell lung cancer and
effect on patient survival. Histol Histopathol.
180272018.PubMed/NCBI
|
|
21
|
Liu G, Xiong D, Zeng J, Chen B and Huang
Z: Clinicopathological and prognostic significance of Ki-67
immunohistochemical expression in gastric cancer: A systematic
review and meta-analysis. Onco Targets Ther. 10:4321–4328. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Min KW, Kim DH, Son BK, Kim DH, Kim EK,
Seo J, Ahn SB, Jo YJ, Park YS and Ha J: A High Ki67/BCL2 index
could predict lower disease-free and overall survival in
intestinal-type gastric cancer. Eur Surg Res. 58:158–168. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishizawa T and Yahagi N: Long-term
outcomes of using endoscopic submucosal dissection to treat early
gastric cancer. Gut Liver. 12:119–124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu H, Liu X, Gong P, Song W, Zhou M, Li Y,
Zhao Z and Fan H: Elevated TFAP4 regulates lncRNA TRERNA1 to
promote cell migration and invasion in gastric cancer. Oncol Rep.
40:923–931. 2018.PubMed/NCBI
|
|
25
|
Yuan J, Zeng J, Shuai C and Liu Y: TWSG1
is a novel tumor suppressor in gastric cancer. DNA Cell Biol.
37:574–583. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ji CD, Wang YX, Xiang DF, Liu Q, Zhou ZH,
Qian F, Yang L, Ren Y, Cui W, Xu SL, et al: Kir2.1 interaction with
Stk38 promotes invasion and metastasis of human gastric cancer by
enhancing MEKK2-MEK1/2-ERK1/2 signaling. Cancer Res. 78:3041–3053.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
George JT, Jolly MK, Xu J, Somarelli J and
Levine H: Survival outcomes in cancer patients predicted by a
partial EMT gene expression scoring metric. Cancer Res.
77:6415–6428. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
El-Sayed IY, Daher A, Destouches D, Firlej
V, Kostallari E, Maillé P, Huet E, Haidar-Ahmad N, Jenster G, de la
Taille A, et al: Extracellular vesicles released by
mesenchymal-like prostate carcinoma cells modulate EMT state of
recipient epithelial-like carcinoma cells through regulation of AR
signaling. Cancer Lett. 410:100–111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Skrypek N, Goossens S, De Smedt E,
Vandamme N and Berx G: Epithelial-to-mesenchymal transition:
Epigenetic reprogramming driving cellular plasticity. Trends Genet.
33:943–959. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dominguez C, David JM and Palena C:
Epithelial-mesenchymal transition and inflammation at the site of
the primary tumor. Semin Cancer Biol. 47:177–184. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
da Silva SD, Alaoui-Jamali MA, Soares FA,
Carraro DM, Brentani HP, Hier M, Rogatto SR and Kowalski LP: TWIST1
is a molecular marker for a poor prognosis in oral cancer and
represents a potential therapeutic target. Cancer. 120:352–362.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sun Y, Xu K, He M, Fan G and Lu H:
Overexpression of Glypican 5 (GPC5) inhibits prostate cancer cell
proliferation and invasion via suppressing Sp1-mediated EMT and
activation of Wnt/β-catenin signaling. Oncol Res. Sep 6–2017.(Epub
ahead of print). View Article : Google Scholar :
|
|
33
|
Yamaguchi H, Du Y, Nakai K, Ding M, Chang
SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, et al: EZH2 contributes to
the response to PARP inhibitors through its PARP-mediated poly-ADP
ribosylation in breast cancer. Oncogene. 37:208–217. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nestal de Moraes G, Ji Z, Fan LY, Yao S,
Zona S, Sharrocks AD and Lam EW: SUMOylation modulates
FOXK2-mediated paclitaxel sensitivity in breast cancer cells.
Oncogenesis. 7:292018. View Article : Google Scholar : PubMed/NCBI
|
